(2R,4'R,8'AR)-1-[2-[4-[[2-(2,4-二氯苯氧基)乙酰基]氨基]苯基]乙酰基]四氢-6'-氧代螺[吡咯烷-2,7'(6'H)-[2H]吡咯并[2,1-B][1,3]噻嗪]-4'-甲酰胺
中文名称 | (2R,4'R,8'AR)-1-[2-[4-[[2-(2,4-二氯苯氧基)乙酰基]氨基]苯基]乙酰基]四氢-6'-氧代螺[吡咯烷-2,7'(6'H)-[2H]吡咯并[2,1-B][1,3]噻嗪]-4'-甲酰胺 |
---|---|
中文同义词 | (2R,4'R,8'AR)-1-[2-[4-[[2-(2,4-二氯苯氧基)乙酰基]氨基]苯基]乙酰基]四氢-6'-氧代螺[吡咯烷-2,7'(6'H)-[2H]吡咯并[2,1-B][1,3]噻嗪]-4'-甲酰胺;化合物 T16937;(2R,4'R,8'AR)-1-[2-[4-[[2-(2,4-二氯苯氧基)乙酰基]氨基]苯基]乙酰基]四氢-6'-氧代螺[吡咯烷-2,7'(6'H)-[2H]吡咯并[2,1-B][1,3]噻嗪]-4'-甲酰胺;(2R,4'R,8A'R)-1-(2-(4-(2-(2,4-二氯苯氧基)乙酰氨基)苯基)乙酰基)-6'-氧代六氢螺[吡咯烷-2,7'-吡咯并[2,1-B][1,3]噻嗪]-4'-甲酰胺;化合物 ST 2825 |
英文名称 | ST 2825 |
英文同义词 | (2R,4'R,8'aR)-1-[2-[4-[[2-(2,4-Dichlorophenoxy)acetyl]amino]phenyl]acetyl]tetrahydro-6'-oxospiro[pyrrolidine-2,7'(6'H)-[2H]pyrrolo[2,1-b][1,3]thiazine]-4'-carboxamide;ST 2825;ST 2825;ST2825;Spiro[pyrrolidine-2,7'(6'H)-[2H]pyrrolo[2,1-b][1,3]thiazine]-4'-carboxamide, 1-[2-[4-[[2-(2,4-dichlorophenoxy)acetyl]amino]phenyl]acetyl]tetrahydro-6'-oxo-, (2R,4'R,8'aR)-;(2R,4'R,8a'R)-1-(2-(4-(2-(2,4-Dichlorophenoxy)acetamido)phenyl)acetyl)-6'-oxotetrahydro-2'H,6'H-spiro[pyrrolidine-2,7'-pyrrolo[2,1-b][1,3]thiazine]-4'-carboxamide;(2R,4'R,8a'R)-1-(2-(4-(2-(2,4-Dichlorophenoxy)acetamido)phenyl)acetyl)-6'-oxotetrahydro-2'H,6'H-spiro[pyrrolidine-2,7'-pyrrolo[2,1-b][1,3]thiazine]-4'-carboxamide |
CAS号 | 894787-30-5 |
分子式 | C27H28Cl2N4O5S |
分子量 | 591.51 |
EINECS号 | |
相关类别 | |
Mol文件 | 894787-30-5.mol |
结构式 |
(2R,4'R,8'AR)-1-[2-[4-[[2-(2,4-二氯苯氧基)乙酰基]氨基]苯基]乙酰基]四氢-6'-氧代螺[吡咯烷-2,7'(6'H)-[2H]吡咯并[2,1-B][1,3]噻嗪]-4'-甲酰胺 性质
沸点 | 939.0±65.0 °C(Predicted) |
---|---|
密度 | 1.51±0.1 g/cm3(Predicted) |
溶解度 | 溶于二甲基亚砜 |
形态 | 固体 |
酸度系数(pKa) | 12.86±0.70(Predicted) |
颜色 | 白色至米白色 |
InChIKey | HBLHLJXFIPCEMW-ZJSFPPFMSA-N |
SMILES | N1(C(CC2=CC=C(NC(COC3=CC=C(Cl)C=C3Cl)=O)C=C2)=O)CCC[C@]21C(=O)N1[C@@H](C(N)=O)CCS[C@]1([H])C2 |
(2R,4'R,8'AR)-1-[2-[4-[[2-(2,4-二氯苯氧基)乙酰基]氨基]苯基]乙酰基]四氢-6'-氧代螺[吡咯烷-2,7'(6'H)-[2H]吡咯并[2,1-B][1,3]噻嗪]-4'-甲酰胺 用途与合成方法
MyD88
ST2825 blocks IL-1R/TLR signaling by interfering with MyD88 homodimerization. ST2825 inhibits this interaction in a concentration-dependent manner with ~40% inhibition of dimerization at 5 μM ST2825 and 80% inhibition at 10 μM ST2825.
ST2825 dose-dependently inhibits IL-1β-induced production of IL-6 in treated mice after oral administration. The animals are administered orally with the appropriate vehicles or ST2825 at doses ranging from 50 to 200 mg/kg, 5 min prior to i.p. injection with 20 μg/kg IL-1β. ST2825 exertes a significant inhibition of IL-1β-stimulated production of IL-6 at 100 and 200 mg/kg.
安全信息
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/08/19 | HY-50937 | (2R,4'R,8'AR)-1-[2-[4-[[2-(2,4-二氯苯氧基)乙酰基]氨基]苯基]乙酰基]四氢-6'-氧代螺[吡咯烷-2,7'(6'H)-[2H]吡咯并[2,1-B][1,3]噻嗪]-4'-甲酰胺 ST 2825 | 894787-30-5 | 1mg | 3302元 |
2023/03/20 | HY-50937 | (2R,4'R,8'AR)-1-[2-[4-[[2-(2,4-二氯苯氧基)乙酰基]氨基]苯基]乙酰基]四氢-6'-氧代螺[吡咯烷-2,7'(6'H)-[2H]吡咯并[2,1-B][1,3]噻嗪]-4'-甲酰胺 ST 2825 | 894787-30-5 | 5mg | 11346元 |